Evoke Pharma Inc - Understand $evok stock

$EVOK Market Cap: $4.372 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$7.526M

TTM

Gross Margin

96.86%

TTM

Net Earnings

-$6.528M

TTM

Current Assets

$12.14M

Q2 2024

Current Liabilities

$9.471M

Q2 2024

Current Ratio

128.14%

Q2 2024

Total Assets

$12.14M

Q2 2024

Total Liabilities

$9.471M

Q2 2024

Book Value

$2.665M

Q2 2024

Cash

$9.200M

Q2 2024

P/E

-0.6697

Oct 17, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$5.181M	$2.509M	$1.618M	$23.02K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	106.51%	55.04%	6929.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$5.181M	$2.509M	$1.618M	$23.02K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$201.9K	$370.4K	$328.1K	$90.00K
Gross Profit	$4.979M	$2.138M	$1.290M	-$60.00K
Gross Profit Margin	96.1%	85.24%	79.72%	-260.64%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$12.23M	$9.624M	$8.851M	$6.429M	$3.738M	$3.920M	$4.090M	$3.590M	$3.660M	$3.160M	$1.640M	$840.0K	$570.0K
YoY Change	27.06%	8.73%	37.68%	71.99%	-4.64%	-4.16%	13.93%	-1.91%	15.82%	92.68%	95.24%	47.37%
% of Gross Profit	245.6%	450.07%	686.16%
Research & Development	$181.9K	$300.8K	$590.5K	$6.555M	$3.416M	$4.095M	$7.137M	$6.952M	$8.154M	$9.992M	$957.0K	$1.166M	$1.844M
YoY Change	-39.52%	-49.06%	-90.99%	91.86%	-16.57%	-42.63%	2.67%	-14.75%	-18.39%	944.1%	-17.9%	-36.79%
% of Gross Profit	3.65%	14.07%	45.77%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$12.61M	$10.29M	$9.770M	$13.07M	$7.154M	$8.015M	$11.23M	$10.54M	$11.82M	$13.15M	$2.602M	$2.002M	$2.415M
YoY Change	22.5%	5.37%	-25.25%	82.69%	-10.73%	-28.64%	6.51%	-10.78%	-10.13%	405.42%	29.93%	-17.07%
Operating Profit	-$7.431M	-$7.786M	-$8.152M	-$13.05M	-$7.154M	-$8.015M	-$11.23M	-$10.54M	-$11.82M	-$13.15M	-$2.602M	-$2.002M	-$2.415M
YoY Change	-4.56%	-4.48%	-37.52%	82.37%	-10.73%	-28.64%	6.51%	-10.78%	-10.13%	405.42%	29.93%	-17.07%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$500.0K	$500.0K	$500.1K	$113.0K	$28.80K	$20.00K	$6.519K	-$268.0K	-$303.2K	$107.8K	$159.9K	-$20.00K	$10.00K
YoY Change	0.0%	-0.01%	342.55%	292.37%	43.99%	206.8%	-102.43%	-11.59%	-381.14%	-32.56%	-899.43%	-300.0%
% of Operating Profit
Other Income/Expense, Net	-$361.4K	-$438.0K	-$386.3K	-$107.3K	$28.80K	$448.6K	-$1.010M	$60.00K		-$97.65K	-$234.6K	-$15.10K	$13.32K
YoY Change	-17.49%	13.38%	259.95%	-472.67%	-93.58%	-144.42%	-1783.33%			-58.38%	1453.68%	-213.34%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$7.792M	-$8.224M	-$8.538M	-$13.15M	-$7.130M	-$7.570M	-$12.23M	-$10.75M	-$12.12M	-$13.25M	-$2.840M	-$2.020M	-$2.400M
YoY Change	-5.25%	-3.68%	-35.07%	84.43%	-5.81%	-38.1%	13.77%	-11.3%	-8.53%	366.55%	40.59%	-15.83%
Income Tax							$0.00				$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.792M	-$8.224M	-$8.538M	-$13.15M	-$7.126M	-$7.566M	-$12.23M	-$10.75M	-$12.12M	-$13.25M	-$2.836M	-$2.018M	-$2.401M
YoY Change	-5.25%	-3.68%	-35.1%	84.61%	-5.82%	-38.14%	13.77%	-11.31%	-8.5%	367.05%	40.59%	-15.98%	-52.35%
Net Earnings / Revenue	-150.41%	-327.83%	-527.66%	-57144.53%
Basic Earnings Per Share	-$2.33	-$2.62	-$3.18				-$0.82	-$1.15
Diluted Earnings Per Share	-$2.33	-$2.62	-$3.183M	-$515.9K	-$319.7K	-$456.0K	-$0.90	-$1.15	-$1.867M	-$2.197M	-$1.198M	-$1.804M	-$2.182M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$4.739M	$9.844M	$9.145M	$8.070M	$5.660M	$5.320M	$7.680M	$9.010M	$8.690M	$14.16M	$24.20M	$120.0K	$870.0K
YoY Change	-51.85%	7.64%	13.32%	42.58%	6.39%	-30.73%	-14.76%	3.68%	-38.63%	-41.49%	20066.67%	-86.21%
Cash & Equivalents	$4.739M	$9.844M	$9.145M	$8.070M	$5.660M	$5.320M	$7.680M	$9.010M	$8.690M	$14.16M	$24.20M	$120.0K	$870.0K
Short-Term Investments
Other Short-Term Assets	$932.6K	$964.5K	$935.3K	$950.0K	$580.0K	$330.0K	$250.0K	$280.0K	$830.0K	$1.070M	$230.0K	$0.00	$40.00K
YoY Change	-3.31%	3.12%	-1.55%	63.79%	75.76%	32.0%	-10.71%	-66.27%	-22.43%	365.22%		-100.0%
Inventory	$481.8K	$289.4K	$185.5K	$240.0K
Prepaid Expenses
Receivables	$673.1K	$624.8K	$295.2K	$20.00K
Other Receivables	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.827M	$11.72M	$10.56M	$9.280M	$6.250M	$5.650M	$7.930M	$9.280M	$9.520M	$15.23M	$24.43M	$120.0K	$910.0K
YoY Change	-41.76%	11.0%	13.8%	48.48%	10.62%	-28.75%	-14.55%	-2.52%	-37.49%	-37.66%	20258.33%	-86.81%
Property, Plant & Equipment	$0.00	$129.1K	$12.43K	$140.0K	$140.0K
YoY Change	-100.0%	938.37%	-91.12%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$241.6K		$0.00	$10.00K	$10.00K	$10.00K	$10.00K	$10.00K	$10.00K	$10.00K	$560.0K	$0.00	$0.00
YoY Change			-100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-98.21%
Total Long-Term Assets	$241.6K	$129.1K	$12.43K	$150.0K	$150.0K	$10.00K	$10.00K	$10.00K	$10.00K	$0.00	$560.0K	$0.00	$0.00
YoY Change	87.2%	938.46%	-91.71%	0.0%	1400.0%	0.0%	0.0%	0.0%		-100.0%
Total Assets	$7.069M	$11.85M	$10.57M	$9.430M	$6.400M	$5.660M	$7.940M	$9.290M	$9.530M	$15.23M	$24.99M	$120.0K	$910.0K
YoY Change
Accounts Payable	$1.712M	$934.3K	$874.0K	$1.270M	$1.030M	$480.0K	$1.050M	$480.0K	$930.0K	$1.010M	$280.0K	$100.0K	$90.00K
YoY Change	83.21%	6.9%	-31.18%	23.3%	114.58%	-54.29%	118.75%	-48.39%	-7.92%	260.71%	180.0%	11.11%
Accrued Expenses	$1.324M	$720.2K	$531.8K	$1.160M	$980.0K	$1.160M	$1.030M	$930.0K	$760.0K	$700.0K	$560.0K	$420.0K	$210.0K
YoY Change	83.83%	35.45%	-54.16%	18.37%	-15.52%	12.62%	10.75%	22.37%	8.57%	25.0%	33.33%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due								$0.00	$150.0K	$130.0K	$1.440M
YoY Change								-100.0%	15.38%	-90.97%
Total Short-Term Liabilities	$3.036M	$1.655M	$1.406M	$7.540M	$2.020M	$1.630M	$2.070M	$1.410M	$1.830M	$1.850M	$2.280M	$570.0K	$330.0K
YoY Change	83.48%	17.7%	-81.36%	273.27%	23.93%	-21.26%	46.81%	-22.95%	-1.08%	-18.86%	300.0%	72.73%
Long-Term Debt	$5.000M	$5.000M	$5.000M	$5.000M	$0.00	$0.00	$0.00	$0.00	$4.230M	$4.200M	$1.510M	$980.0K	$0.00
YoY Change	0.0%	0.0%	0.0%					-100.0%	0.71%	178.15%	54.08%
Other Long-Term Liabilities	$1.612M	$1.112M	$612.3K	$110.0K		$0.00	$3.700M	$4.100M			$10.00K
YoY Change	44.95%	81.66%	456.64%			-100.0%	-9.76%
Total Long-Term Liabilities	$6.612M	$6.112M	$5.612M	$5.110M	$0.00	$0.00	$3.700M	$4.100M	$4.230M	$4.200M	$1.520M	$980.0K	$0.00
YoY Change	8.18%	8.91%	9.83%			-100.0%	-9.76%	-3.07%	0.71%	176.32%	55.1%
Total Liabilities	$9.648M	$7.767M	$7.018M	$12.65M	$2.020M	$1.630M	$5.780M	$5.510M	$6.070M	$6.040M	$3.800M	$1.550M	$330.0K
YoY Change	24.22%	10.67%	-44.52%	526.24%	23.93%	-71.8%	4.9%	-9.23%	0.5%	58.95%	145.16%	369.7%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2017	2016
Basic Shares Outstanding	3.343M	3.144M	2.682M	14.90M	9.338M
Diluted Shares Outstanding	3.343M	3.144M	2.682M	14.95M	9.338M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $4.372 Million

About Evoke Pharma Inc

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The firm operates through the development and commercialization of pharmaceutical products. The company is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The company developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. The company has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Industry: Pharmaceutical Preparations Peers: Enveric Biosciences Inc Avenue Therapeutics Inc KIORA PHARMACEUTICALS INC Grapefruit USA, Inc GREEN HYGIENICS HOLDINGS INC. Johnson & Johnson One World Products Inc NovaBay Pharmaceuticals, Inc. Sonoma Pharmaceuticals Inc Stem Holdings, Inc.